Hormonal
Once-weekly subcutaneous semaglutide (2.4 mg) combined with lifestyle intervention produces sustained, clinically significant weight loss in adults with overweight or obesity, significantly outperforming placebo.
If you have obesity or overweight with related health conditions, adding once-weekly semaglutide (2.4 mg) to a reduced-calorie diet and exercise program can lead to substantial, sustained weight loss (averaging nearly 15% of body weight) compared to lifestyle changes alone. Be prepared for potential gastrointestinal side effects like nausea, which usually improve over time, and adhere to the titration schedule to minimize discomfort.
In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight.
Why this rating
Large-scale, randomized, double-blind, placebo-controlled Phase 3 trial (STEP 1) with 1,961 participants.
Source
Once-Weekly Semaglutide in Adults with Overweight or Obesity
John Wilding et al. · New England Journal of Medicine · 2021
DOI 10.1056/nejmoa2032183
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →